Last reviewed · How we verify
HB VAX PRO™
At a glance
| Generic name | HB VAX PRO™ |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc (PHASE4)
- Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB VAX PRO™ CI brief — competitive landscape report
- HB VAX PRO™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI